Circulating microRNAs, miR-143, miR-100 and miR-92, as non-invasive biomarkers for bladder cancer diagnosis / Taghried Mahmoud Ibrahim Hellaly ; Supervised Tarek Mohamed Motawi , Sherine Maher Rizk , Ihab abdel Rahman Ibrahim
Material type: TextLanguage: English Publication details: Cairo : Taghried Mahmoud Ibrahim Hellaly , 2017Description: 121 P. : charts ; 25cmOther title:- ميكرو أر إن إيه 143: ميكرو أر إن إيه 100و ميكرو أر إن إيه 92 كدلائل حيوية غير غازية لتشخيص سرطان المثانة [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
Thesis | قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.08.02.Ph.D.2017.Ta.C (Browse shelf(Opens below)) | Not for loan | 01010110073412000 | |||
CD - Rom | مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.08.02.Ph.D.2017.Ta.C (Browse shelf(Opens below)) | 73412.CD | Not for loan | 01020110073412000 |
Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Chemistry
The application of microRNAs (miRNAs) as potential biomarkers and therapy targets has been widely investigated in many kinds of cancers. Recent advantages of serum miRNAs open a new realm of possibilities for noninvasive diagnosis and prognosis of bladder cancer (BC). The aim of our study was to identify plasma miR-92a, miR-100 and miR-143 expression signatures in patients with BC to introduce new markers for establishing BC diagnosis and prognosis. Blood samples were collected from 70 BC patients and 62 controls. Expression of 3 target miRNAs (miR-92a, miR-100 and miR-143) was measured using a quantitative real-time PCR method. The results were correlated with clinicopathological data and analyzed. Plasma levels of miR-92a, miR-100, and miR-143 were significantly lower in BC patients than in the control group. Receiver operator characteristic (ROC) analysis revealed that the sensitivity and specificity values of miR-92a were 97.1% and 76.7%, respectively, with a cut-off value of 0.573. The sensitivity and specificity values of miR-100 were 90% and 66.7%, respectively, with a cut-off value of 0.644. The sensitivity and specificity values of miR-143 were 78.6% and 93.3%, respectively, with a cut-off value of 0.164. This study explores the existence of specific plasma miRNAs as early diagnostic biomarkers for BC in Egyptian patients; and these findings suggest that plasma miR-92a, miR-100 and miR-143 could be a promising novel circulating biomarkers in clinical detection of BC
Issued also as CD
There are no comments on this title.